UK Bio Industry Calls for "Democratized" Investment Opportunities
The UK BioIndustry Association (BIA) has called on the government to introduce a new venture capital fund structure that will give the public the opportunity to be partners in the biotech revolution. The BIA argues that many existing venture capital funds are too bureaucratic for the general public and don’t invest in the UK’s growing cohort of innovative biotech companies. The trade association’s proposed fund structure would offer income and capital gains tax reliefs with a minimal-bureaucracy system for claiming, and allow pooling of capital in a diversified portfolio to spread risk. Individuals who stay invested for longer-periods – which is critical for knowledge-intensive companies conducting R&D – will be rewarded with further income tax relief. BIA CEO Steve Bates commented: “The UK has world-leading bioscience companies that are delivering for patients and investors but too few people have the opportunity to share in their financial success. The fund structure we’re proposing will democratize opportunities to share in the success of UK bioscience and provide much-needed long-term capital for the UK’s most innovative companies.”
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.
